AstraZeneca seals the deal for Almirall’s respiratory meds

Emily Wasserman With generic and branded rivals inching up on AstraZeneca's blockbuster respiratory drug Symbicort, the pharma giant has a game plan locked, loaded and ready to ...

Bristol-Myers beefs up fibrosis pipeline with $444M option deal

John Carroll Bristol-Myers Squibb has grabbed an option on an early-stage program for idiopathic pulmonary fibrosis this morning, forging a deal to potentially buy out Denmark's ...

Pfizer CEO: ‘No reason’ we can’t do an inversion deal, Treasury rules or no

Tracy Staton Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas. Despite the U.S. government's attempt to discourage tax inversions–like ...

Astellas backs out of a $760M Alzheimer’s deal with CoMentis

Damian Garde Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $ 760 million. FierceBiotech ...

Impax gets products, manufacturing with $700M deal for allergy-drug makers

Carly Helfand Back in August, Impax Laboratories CEO Fred Wilkinson told investors on a conference call that the company was "well-positioned to execute on a number of transactions." ...

UPDATED: Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up

John Carroll Novartis is prepping new studies that will test how well three of its oncology drugs–the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia–do ...

Is Teva knocking on Mylan’s door? With inversion deal at risk, maybe

Carly Helfand Teva and Mylan merge? Rumors are certainly swirling–and not for the first time, either. But while a potential deal might make financial sense, at least one analyst ...

Baxter backs Rockwell with a $45M hemodialysis deal

Damian Garde Kidney drug developer Rockwell Medical picked up a big co-sign from a leader in the space, signing a deal with Baxter International that will help pay the way for its late-stage ...

Could political pressure be stalling Hospira’s Danone inversion deal?

Carly Helfand Many a U.S. drugmaker has pounced on an opportunity to pick up a foreign company, haul overseas and reap the tax rewards. But while rumors this summer said Illinois-based ...

Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall’s lung meds

Tracy Staton AstraZeneca has agreed to pay $ 875 million up front–and up to $ 2.2 billion total, with milestones–for Almirall's respiratory portfolio. The deal brings ...

As legislator rails on potential Valeant-Allergan deal, Wall Street lines up to fund it

Carly Helfand It remains to be seen whether unconventional M&A tactics from Valeant's takeover partner, Bill Ackman, will help the pair get a deal for Allergan done. But in ...

Bristol-Myers inks Asia immunotherapy deal with Japan’s Ono

Emily Mullin In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS